The Show Must Go On

An Update on Clinical Experiences and Clinical Studies on Novel Pharmaceutical Developments for the Treatment of Atopic Dermatitis

Tatjana Honstein; Thomas Werfel


Curr Opin Allergy Clin Immunol. 2020;20(4):386-394. 

In This Article

Targeting IL-33 for the Treatment of Atopic Dermatitis With Etokimab

Interleukin-33 is mainly produced by keratinocytes in the skin and has substantial effects on in a lymphoid cells and T cells in cutaneous inflammation, as discussed in further detail by Topal et al.[29] in this issue of COAI. In a first-in-class phase 2a study of etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody was tested in patients with atopic dermatitis.[37] Twelve adult patients with moderate-to-severe atopic dermatitis received a single intravenous systemic administration of etokimab. More than 80% of them achieved EASI50 and 33% EASI75 at day 29 after administration. The authors describe significant reduction in skin neutrophil infiltration after etokimab compared with placebo upon skin challenge with house dust mite and inhibition of neutrophil migration to skin interstitial fluid in vitro.